| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3315237 | Journal of Hepatology | 2006 | 11 Pages |
Abstract
Daily dosing of CIFN plus ribavirin may be a promising concept for selected non-responder patients before considering therapies which are anti-viral but not curative. However, motivation and compliance are requisites and a CIFN induction is not required.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Markus Cornberg, Johannes Hadem, Eva Herrmann, Frank Schuppert, Hartmut H.-J. Schmidt, Markus Reiser, Oliver Marschal, Martin Steffen, Michael P. Manns, Heiner Wedemeyer,